Edition:
United States

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

1.32USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.32
Open
$1.33
Day's High
$1.33
Day's Low
$1.27
Volume
37,142
Avg. Vol
40,804
52-wk High
$35.70
52-wk Low
$1.27

Latest Key Developments (Source: Significant Developments)

CVI Investments Reports 8.8 Pct Passive Stake In Dare Bioscience As Of Feb 13
Thursday, 22 Feb 2018 09:22am EST 

Feb 22 (Reuters) - CVI Investments :CVI INVESTMENTS REPORTS AN 8.8 PERCENT PASSIVE STAKE IN DARÉ BIOSCIENCE AS OF FEB 13- SEC FILING.  Full Article

Dare Bioscience Inc To Raise About $10.25 Mln
Tuesday, 13 Feb 2018 09:18am EST 

Feb 13 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. TO RAISE APPROXIMATELY $10.25 MILLION.DARE BIOSCIENCE -EACH SHARE BEING SOLD TOGETHER WITH WARRANT TO BUY UP TO .70 OF A SHARE OF COMMON STOCK, AT EXERCISE PRICE OF $3.00/SHARE.  Full Article

Daré Bioscience Announces Proposed Public Offering Of Common Stock
Monday, 12 Feb 2018 08:57pm EST 

Feb 13 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.DARE BIOSCIENCE - INTENDS TO OFFER PRIMARY SHARES OF ITS COMMON STOCK AND WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK IN A PUBLIC OFFERING.  Full Article

Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD
Monday, 12 Feb 2018 08:00am EST 

Feb 12 (Reuters) - Dare Bioscience Inc ::DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER.DARE BIOSCIENCE INC - ‍ENTERED INTO AN AGREEMENT TO LICENSE SST-6007​.DARE BIOSCIENCE INC - ‍DARÉ ANTICIPATES COMMENCING A PHASE 2B CLINICAL TRIAL IN SECOND HALF OF 2018 FOR SST-6007​.  Full Article

Dare Bioscience Says Entered Into Common Stock Sales Agreement
Thursday, 4 Jan 2018 08:30am EST 

Jan 4 (Reuters) - Dare Bioscience Inc ::DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING.DARE BIOSCIENCE - UNDER AGREEMENT, CO MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $10 MILLION.  Full Article

Daré Bioscience announces MoU with CONRAD for conduct of Ovaprene postcoital test clinical trial
Monday, 24 Jul 2017 08:30am EDT 

July 24 (Reuters) - Dare Bioscience Inc ::Daré Bioscience, Inc announces memorandum of understanding with Conrad for the conduct of the Ovaprene® postcoital test clinical trial.Final details will be negotiated under a separate agreement.  Full Article

Cerulean Pharma estimates cash, cash equivalents as of June 30,
Monday, 17 Apr 2017 04:45pm EDT 

April 17 (Reuters) - Cerulean Pharma Inc ::Cerulean Pharma-estimates cash, cash equivalents as of june 30, assuming has not consummated transactions under novartis apa or dar*pa, to be $4 million-$6 million.Cerulean Pharma-in event that dar*pa deal does not close board may elect to dissolve co,liquidate assets whether under title 7 or title 11 of u.s. Code.Cerulean Pharma-if board decides to dissolve assets,would be required to pay all of debts, obligations, among others, before distribution to stockholders.Cerulean Pharma-expects that amount of cash left, if any, to distribute to stockholders would be materially less than expected amounts set forth as of june 30.  Full Article

Cerulean Pharma and Daré Bioscience enter into stock purchase agreement
Monday, 20 Mar 2017 08:00am EDT 

Cerulean Pharma Inc : Cerulean pharma and daré bioscience enter into stock purchase agreement . Cerulean pharma inc - cerulean enters into two agreements to sell assets . Cerulean pharma inc- cerulean pays off debt facility and announces reduction in force . Cerulean pharma inc - stockholders of daré bioscience will receive shares of newly issued cerulean common stock . Cerulean pharma inc - outstanding daré bioscience options and convertible securities will be assumed by cerulean . Cerulean pharma inc - sabrina martucci johnson to be named ceo of combined company . Cerulean pharma inc - transaction has been unanimously approved by boards of directors of both companies . Cerulean pharma inc - cerulean sold its clinical product candidates, crlx101 and crlx301, for $1.5 million to bluelink pharmaceuticals . Cerulean pharma inc - cerulean also entered into an agreement with novartis . Cerulean pharma inc-in connection with the transactions, it is paying off its debt facility with hercules capital, inc. . Cerulean pharma inc - novartis will acquire all rights to cerulean's dynamic tumor targeting(tm) platform for $6 million . Cerulean pharma-board of combined company will consist of five members, three to be designated by daré and two to be designated by cerulean . Cerulean pharma inc- upon close of proposed transaction, board of directors of combined company will consist of five members.  Full Article

Cerulean Pharma reports Q3 2016 financial results
Thursday, 3 Nov 2016 04:11pm EDT 

Cerulean Pharma Inc - : Announced reduction in force of approximately 48% percent, which company expects to be substantially completed by end of 2016 . Announced reduction in force of approximately 48% percent, which company expects to be substantially completed by end of 2016 . In quarter, announced 5-target collaboration with novartis to combine Co's proprietary NDC technology with Novartis-selected compounds .Cerulean reports third quarter 2016 financial results and provides corporate update.  Full Article

Cerulean Pharma says reducing workforce by about 48 pct
Thursday, 18 Aug 2016 04:01pm EDT 

Cerulean Pharma Inc : Cerulean announces reduction in force . Says reducing its workforce by about 48 pct, to a total of 23 full-time equivalent employees . Says expects reduction plan to be substantially completed by end of 2016 . Says workforce reduction is designed to reduce operating expenses while co refocuses its clinical strategy for CRLX101 .Expects reduction in force to result in about $5 million in reduced annualized operating expenses.  Full Article

BRIEF-Empery Asset Management Lp Reports 9.05 pct Passive Stake In Dare Bioscience As Of Feb 13

* EMPERY ASSET MANAGEMENT LP REPORTS 9.05 PERCENT PASSIVE STAKE IN DARE BIOSCIENCE INC AS OF FEB 13, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2CC1wzx) Further company coverage: